** Shares of drug developer Acelyrin SLRN.O rise 17.05% to $2.54 premarket
** SLRN confirms that private affiliate of investor Tang Capital Partners, Concentra Biosciences, has proposed to acquire it for $3 per share in cash, a 38.2% premium to its last closing price
** The offer implies an equity value of about $300 million, according to Reuters calculations, plus a "contingent value right"
** The investor had a 5.3% stake in SLRN - filing
** Earlier this month, SLRN announced an agreement to merge with Alumis ALMS.O in an all-stock transaction
** SLRN shares have fallen nearly 38% since it reported mid-stage data from its thyroid eye disease drug in early January
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.